- $766.88m
- $537.68m
- $0.58m
- 37
- 21
- 78
- 42
Annual balance sheet for Icosavax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 23.1 | 13.1 | 279 | 218 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 23.3 | 16.2 | 287 | 224 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0 | 0.01 | 1.08 | 14.8 |
| Total Assets | 23.3 | 16.2 | 288 | 239 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 1.22 | 5.83 | 9.24 | 13.8 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 1.47 | 12.8 | 9.41 | 20.5 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 21.8 | 3.36 | 278 | 218 |
| Total Liabilities & Shareholders' Equity | 23.3 | 16.2 | 288 | 239 |
| Total Common Shares Outstanding |